NASDAQ:GNCA - Genocea Biosciences Stock Price, Forecast & News

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

Genocea Biosciences Inc (NASDAQ:GNCA) issued its quarterly earnings results on Thursday, October, 24th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.17. View Genocea Biosciences' Earnings History.

Genocea Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Genocea Biosciences.

5 analysts have issued 1-year price targets for Genocea Biosciences' shares. Their forecasts range from $7.00 to $32.00. On average, they expect Genocea Biosciences' share price to reach $16.33 in the next year. This suggests a possible upside of 642.4% from the stock's current price. View Analyst Price Targets for Genocea Biosciences.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genocea Biosciences.

News coverage about GNCA stock has trended extremely negative this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Genocea Biosciences earned a coverage optimism score of -4.5 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Genocea Biosciences.

Genocea Biosciences saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 97,500 shares, an increase of 18.5% from the December 31st total of 82,300 shares. Based on an average daily trading volume, of 131,500 shares, the short-interest ratio is presently 0.7 days. Approximately 0.7% of the shares of the stock are sold short. View Genocea Biosciences' Current Options Chain.

Some companies that are related to Genocea Biosciences include Jounce Therapeutics (JNCE), La Jolla Pharmaceutical (LJPC), LogicBio Therapeutics (LOGC), Windtree Therapeutics (WINT), Solid Biosciences (SLDB), Applied Genetic Technologies (AGTC), Dyadic International (DYAI), Erytech Pharma (ERYP), Fennec Pharmaceuticals (FENC), X4 Pharmaceuticals (XFOR), Axcella Health (AXLA), Cidara Therapeutics (CDTX), Gamida Cell (GMDA), Polarityte (PTE) and Acorda Therapeutics (ACOR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Hudson Technologies (HDSN), Micron Technology (MU), Accenture (ACN) and AutoZone (AZO).

Genocea Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (1.05%) and Wedbush Securities Inc. (0.07%). Company insiders that own Genocea Biosciences stock include George Siber, Michael Alfieri and Peter W Sonsini. View Institutional Ownership Trends for Genocea Biosciences.

GNCA stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC and Wedbush Securities Inc.. Company insiders that have bought Genocea Biosciences stock in the last two years include George Siber, Michael Alfieri and Peter W Sonsini. View Insider Buying and Selling for Genocea Biosciences.

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GNCA stock can currently be purchased for approximately $2.20.

Genocea Biosciences has a market capitalization of $57.53 million. The biotechnology company earns $-27,810,000.00 in net income (profit) each year or ($3.68) on an earnings per share basis. Genocea Biosciences employs 61 workers across the globe.View Additional Information About Genocea Biosciences.

The official website for Genocea Biosciences is http://www.genocea.com/.

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]